Filing Details

Accession Number:
0001209191-21-007638
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-03 21:39:39
Reporting Period:
2021-02-01
Accepted Time:
2021-02-03 21:39:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1652130 Intellia Therapeutics Inc. NTLA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1563584 M John Leonard C/O Intellia Therapeutics, Inc.
40 Erie Street; Suite 130
Cambridge MA 02139
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-01 100,000 $6.83 575,488 No 4 M Direct
Common Stock Disposition 2021-02-01 16,750 $63.32 558,738 No 4 S Direct
Common Stock Disposition 2021-02-01 26,058 $64.13 532,680 No 4 S Direct
Common Stock Disposition 2021-02-01 8,827 $65.00 523,853 No 4 S Direct
Common Stock Acquisiton 2021-02-01 10,000 $13.88 533,853 No 4 M Direct
Common Stock Disposition 2021-02-01 1,709 $63.24 532,144 No 4 S Direct
Common Stock Disposition 2021-02-01 3,497 $64.16 528,647 No 4 S Direct
Common Stock Disposition 2021-02-01 693 $65.02 527,954 No 4 S Direct
Common Stock Acquisiton 2021-02-01 30,000 $18.30 557,954 No 4 M Direct
Common Stock Disposition 2021-02-01 6,448 $63.29 551,506 No 4 S Direct
Common Stock Disposition 2021-02-01 9,432 $64.09 542,074 No 4 S Direct
Common Stock Disposition 2021-02-01 3,260 $65.03 538,814 No 4 S Direct
Common Stock Acquisiton 2021-02-01 60,000 $22.78 598,814 No 4 M Direct
Common Stock Disposition 2021-02-01 11,100 $63.30 587,714 No 4 S Direct
Common Stock Disposition 2021-02-01 16,640 $64.10 571,074 No 4 S Direct
Common Stock Disposition 2021-02-01 5,475 $65.04 565,599 No 4 S Direct
Common Stock Acquisiton 2021-02-03 50,000 $22.78 615,599 No 4 M Direct
Common Stock Disposition 2021-02-03 30,998 $72.00 584,601 No 4 S Direct
Common Stock Acquisiton 2021-02-03 67,060 $13.88 651,661 No 4 M Direct
Common Stock Disposition 2021-02-03 36,858 $73.00 614,803 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-02-01 100,000 $0.00 100,000 $6.83
Common Stock Stock Option (right to buy) Disposition 2021-02-01 10,000 $0.00 10,000 $13.88
Common Stock Stock Option (right to buy) Disposition 2021-02-01 30,000 $0.00 30,000 $18.30
Common Stock Stock Option (right to buy) Disposition 2021-02-01 60,000 $0.00 60,000 $22.78
Common Stock Stock Option (right to buy) Disposition 2021-02-03 50,000 $0.00 50,000 $22.78
Common Stock Stock Option (right to buy) Disposition 2021-02-03 67,060 $0.00 67,060 $13.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
125,234 2026-02-02 No 4 M Direct
85,000 2027-01-05 No 4 M Direct
27,500 2027-12-11 No 4 M Direct
160,000 2028-01-24 No 4 M Direct
110,000 2028-01-24 No 4 M Direct
17,940 2027-01-05 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 58,415 Indirect By Trust
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.69 to $63.685, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.69 to $64.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.70 to $65.48, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.74 to $63.545, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.75 to $64.65, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.865 to $65.09, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.68 to $63.67, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.70 to $65.37, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
  10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.69 to $63.68, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
  11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.69 to $64.66, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
  12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.76 to $65.40, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 1, 2021 at each separate price.
  13. Shares held by the John M. Leonard 2015 Irrevocable Trust.
  14. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and has vested in full on February 3, 2020.
  15. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and vested in full on January 6, 2021.
  16. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 55,885 shares as of February 1, 2021.
  17. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 165,000 shares as of February 1, 2021.
  18. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 165,000 shares as of February 1, 2021.
  19. The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 95,000 shares as of February 1, 2021.